Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix announces its total number of shares and voting rights as of September 30, 2021. The company had 34,825,872 outstanding shares with 35,999,889 total voting rights gross and 35,986,273 total voting rights net. This report complies with the French Commercial Code and the General Regulations of the Autorité des Marchés Financiers. As a clinical biotechnology company, Nanobiotix focuses on innovative therapeutic approaches in oncology with its lead candidate NBTXR3 already authorized in Europe for treating soft tissue sarcoma under the brand name Hensify®.
NANOBIOTIX (NASDAQ: NBTX) announced five presentations at the ASTRO 2021 Annual Meeting, from October 24-27. Key highlights include:
- Poster presentation by Pr. Christophe Le Tourneau on phase I data for NBTXR3 in head and neck cancer.
- Oral presentation by Dr. Tanguy Y. Seiwert discussing NBTXR3's potential effects as a single agent and with anti-PD-1.
- Dr. Sylvie Bonvalot's follow-up on phase II/III STS study.
NBTXR3, a novel oncology product, is designed for use with radiotherapy, showing promise in treating solid tumors.
Nanobiotix (NASDAQ: NBTX) announced the publication of preclinical data in the International Journal of Radiation Oncology, showcasing the potential of NBTXR3 combined with radiotherapy and anti-PD-1 to enhance tumor treatment. The study reveals that NBTXR3 effectively controls tumor growth in both sensitive and resistant models, improves immune response, and reduces metastasis. This research supports NBTXR3's exploration as a novel treatment option for metastatic lung cancer, aiming to convert irradiated tumors into 'self-vaccines' for broader therapeutic use.
Nanobiotix has reported its latest shareholder information in compliance with French regulations. As of August 31, 2021, the company has 34,825,872 outstanding shares and 36,019,979 voting rights gross, with 36,010,846 voting rights net. Founded in 2003, Nanobiotix is a biotechnology firm focusing on innovative therapies, particularly for oncology, and is listed on both Euronext Paris and NASDAQ under the symbol NBTX.
Nanobiotix reported significant operational advancements and financial results for H1 2021. The Company achieved an impressive 82.5% overall objective response rate and 62.5% complete response rate in vulnerable elderly patients from Study 102, supporting a pivotal Phase III study set to commence in late Q4 2021.
Financially, cash and equivalents totaled €102.3 million, expected to fund operations into Q1 2023. However, net loss increased to €30.4 million, reflecting higher R&D and SG&A expenses. Revenue stood at €9.7 thousand, a decrease from the previous year.
NANOBIOTIX (NASDAQ: NBTX), a biotechnology firm focused on cancer treatment, announced that CEO Laurent Levy will present the company's latest developments at the virtual H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be accessible on-demand starting at 7:00 AM EDT on September 13, 2021. The company is known for its innovative physics-based therapeutic approaches and holds numerous patents in oncology and other fields. For further details, visit www.nanobiotix.com.
NANOBIOTIX (NASDAQ: NBTX) reported its operational progress and cash position for Q2 2021, revealing total revenue of €9.7k for the first half, a significant drop from €36.9k in H1 2020. The company’s cash reserves decreased slightly to €102.3 million, bolstered by a €20 million upfront payment from its collaboration with LianBio. Key operational highlights included promising clinical data for NBTXR3 in head and neck cancer, as well as a strategic partnership with LianBio for development in Asia. A pivotal phase III study for NBTXR3 is planned in late 2021.
NANOBIOTIX (NASDAQ: NBTX) announced the initiation of a phase I clinical study of NBTXR3 combined with radiation therapy for treating inoperable recurrent non-small cell lung cancer (NSCLC). This study is one of five recruiting collaborations at The University of Texas MD Anderson Cancer Center. NBTXR3, a unique oncology product, is designed to enhance tumor cell death through a one-time intratumoral injection. The company aims to expand NBTXR3's applications across solid tumors while focusing on head and neck cancer and immunotherapy.
NANOBIOTIX (NASDAQ: NBTX) announced a virtual KOL event on June 11, 2021, at 8 AM ET, targeting analysts, investors, and the scientific community. The event will showcase key opinion leaders discussing the immunotherapy data from the 2021 ASCO Annual Meeting and the first-in-class radioenhancer NBTXR3's role in oncology. Highlights include presentations on NBTXR3's mode of action, safety and efficacy updates, and its potential as a combination-agnostic product. Registration for the event is open, and the webcast will be available for later viewing.
Nanobiotix (NASDAQ: NBTX) announced updated data on its immunotherapy product NBTXR3 at the 2021 ASCO Meeting. The data shows promising results in treating advanced cancer patients with NBTXR3 combined with radiotherapy and anti-PD-1 therapy. Out of 13 evaluable patients, 76.9% demonstrated tumor regression. Notably, 80% of anti-PD-1 naïve patients had tumor regression, and 75% of previously resistant patients showed tumor regression. The study supports NBTXR3's potential to enhance immune responses against cancer, addressing significant unmet needs in immunotherapy.